Lead sponsor
China National Center for Cardiovascular Diseases
1 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
1
Trials led
1
Active
116
Total enrollment
1
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 4
1
Trials by status
Not yet recruiting
1
Trials led
TrialKey I/E criterionPhaseStatusEnrollment
Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or ObesityBMI ≥28Ph 4Not yet recruiting116